Thymosin Alpha-1 vs LL-37 (Cathelicidin)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.

Full details →

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

Side-by-Side Comparison

AspectThymosin Alpha-1LL-37 (Cathelicidin)
MechanismEnhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes.Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.
Typical DosageClinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary.Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.
AdministrationSubcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols.Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.
Side EffectsGenerally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue.Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.
Best For

What They Have in Common

Both Thymosin Alpha-1 and LL-37 (Cathelicidin) are commonly used for:

Ready to Learn More?